Preferred Label : Medulloblastoma;
Symbol : MDB;
CISMeF acronym : MBEN; MDB;
Type : Phenotype, molecular basis known;
Alternative titles and symbols : Medulloblastoma predisposition syndrome;
Description : Medulloblastoma is the most common brain tumor in children. It accounts for 16% of
all pediatric brain tumors, and 40% of all cerebellar tumors in childhood are medulloblastoma.
Medulloblastoma occurs bimodally, with peak incidences between 3 and 4 years and 8
and 9 years of age. Approximately 10 to 15% of medulloblastomas are diagnosed in infancy.
Medulloblastoma accounts for less than 1% of central nervous system (CNS) tumors in
adults, with highest incidence in adults 20 to 34 years of age. In 1 to 2% of patients,
medulloblastoma is associated with Gorlin syndrome (109400), a nevoid basal carcinoma
syndrome. Medulloblastoma also occurs in up to 40% of patients with Turcot syndrome
(276300). Medulloblastoma is thought to arise from neural stem cell precursors in
the granular cell layer of the cerebellum. Standard treatment includes surgery, chemotherapy,
and, depending on the age of the patient, radiation therapy (Crawford et al., 2007).;
Inheritance : Autosomal dominant; Autosomal recessive; Somatic mutation;
Molecular basis : Caused by somatic mutation in the patched 2 gene (PTCH2, 603673.0001); Caused by somatic mutation in the catenin beta 1 gene (CTNNB1, 116806.0007); Caused by mutation in the BRCA2 gene (BRCA2, 600185.0027); Caused by mutation in the SUFU negative regulator of hedgehog signaling gene (SUFU,
607035.0005);
Neoplasia : Medulloblastoma;
Laboratory abnormalities : Loss of heterozygosity for 17p sequences in 45% of medulloblastomas; Isochromosome 17q frequent in cytogenetic studies;
Prefixed ID : #155255;
Origin ID : 155255;
UMLS CUI : C0025149;
Automatic exact mappings (from CISMeF team)
Currated CISMeF NLP mapping
DO Cross reference
Genes related to phenotype
HPO term(s)
ORDO concept(s)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to BTNT